Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The epigenetic regulator RINF (CXXC5) maintains SMAD7 expression in human immature erythroid cells and sustains red blood cells expansion.
Astori A, Matherat G, Munoz I, Gautier EF, Surdez D, Zermati Y, Verdier F, Zaidi S, Feuillet V, Kadi A, Lauret E, Delattre O, Lefèvre C, Fontenay M, Ségal-Bendirdjian E, Dusanter-Fourt I, Bouscary D, Hermine O, Mayeux P, Pendino F. Astori A, et al. Among authors: pendino f. Haematologica. 2022 Jan 1;107(1):268-283. doi: 10.3324/haematol.2020.263558. Haematologica. 2022. PMID: 33241676 Free PMC article.
Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.
Bruserud Ø, Reikvam H, Fredly H, Skavland J, Hagen KM, van Hoang TT, Brenner AK, Kadi A, Astori A, Gjertsen BT, Pendino F. Bruserud Ø, et al. Among authors: pendino f. Oncotarget. 2015 Feb 20;6(5):2794-811. doi: 10.18632/oncotarget.3056. Oncotarget. 2015. PMID: 25605239 Free PMC article.
CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.
Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø. Astori A, et al. Among authors: pendino f. Oncotarget. 2013 Sep;4(9):1438-48. doi: 10.18632/oncotarget.1195. Oncotarget. 2013. PMID: 23988457 Free PMC article.
Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.
Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO. Gausdal G, et al. Among authors: pendino f. Cell Death Dis. 2013 Feb 28;4(2):e516. doi: 10.1038/cddis.2013.39. Cell Death Dis. 2013. PMID: 23449452 Free PMC article.
Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.
Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, da Costa Reis Monte Mor B, Massé A, Le Couédic JP, Pendino F, Carbonne B, Larghero J, Ravanat JL, Casadevall N, Bernard OA, Droin N, Solary E, Godley LA, Vainchenker W, Plo I, Delhommeau F. Pronier E, et al. Among authors: pendino f. Blood. 2011 Sep 1;118(9):2551-5. doi: 10.1182/blood-2010-12-324707. Epub 2011 Jul 6. Blood. 2011. PMID: 21734233 Free PMC article.
24 results